Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia

MeSH terms

• Adverse Drug Reaction Reporting Systems / trends
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use
• Choice Behavior
• Dasatinib
• Health Services Needs and Demand / trends*
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Neoadjuvant Therapy / methods*
• Protein Kinase Inhibitors / adverse effects*
• Protein Kinase Inhibitors / therapeutic use*
• Protein-Tyrosine Kinases / antagonists & inhibitors
• Pyrimidines / adverse effects
• Pyrimidines / therapeutic use
• Research Design / standards
• Research Design / trends
• Risk Assessment / methods
• Risk Factors
• Thiazoles / adverse effects
• Thiazoles / therapeutic use